Spine Wave to Study Second Generation NuCore Injectable Nucleus Device

Spine Wave, a Shelton, Conn.-based spine device company, has initiated a clinical study in Europe to gather data on the second generation of its NuCore Injectable Nucleus Device for the percutaneous treatment of degenerative disc disease, according to a Spine Wave news release.

Advertisement

The NuCore material is made from a synthetic polymer designed to mimic the properties of a natural nucleus. The new version of the device includes a transient radiopacifier for the intraoperative visualization of the material using fluoroscopy during the percutaneous injection.

The new study will be added to existing data from 68 patients with a two-year follow up.

Related Articles on Spine Devices:

Neuralstem Receives Approval for Cervical Spine Neural Stem Cell Injections to Treat ALS

Synthes Quarterly Revenues Break $1B for the First Time, Thanks to International Markets

K2M Hires 3 New International Team Leaders

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.